BIT225 active against SARS-CoV-2 in an animal model of COVID-19

Показать описание

Biotron Limited (ASX:BIT) held a webinar today to update investors on its latest news on its lead clinical stage antiviral drug BIT225. BIT225 has shown significant and clinically relevant activity in an animal model of COVID-19. The drug prevented the development of severe disease, reduced pro-inflammatory cytokines associated with "cytokine storms" that are linked to severe disease and respiratory distress, and reduced viral levels in lungs and blood. BIT225 has extensive clinical experience through 9 completed clinical trials; it is currently in development for HIV-1 eradication. It is an oral drug with a well characterised safety profile, and the company plans to progress it as quickly as possible into human studies for treatment of COVID-19.